Alerts will be sent to your verified email
Verify EmailNATCOPHARM
Natco Pharma
|
Alembic Pharma
|
Caplin Point Lab
|
|
---|---|---|---|
Operational Metrics
|
|||
API Sector
|
|||
US DMF Filings
|
58.0 . | 135.0 . | n/a |
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
51.0 . | 263.0 . | 46.0 . |
Number of ANDA's Approved By USFDA
|
41.0 . | 219.0 . | 33.0 . |
Domestic Sales Growth - YoY
|
31.2 % | n/a | n/a |
R&D as a % of Total Sales
|
7.6 % | 7.0 % | 4.4 % |
Financials
|
|||
5 yr Average ROE
|
13.06 % | 15.79 % | 20.61 % |
5yr average Equity Multiplier
|
1.18 | 1.48 | 1.17 |
5yr Average Asset Turnover Ratio
|
0.46 | 0.83 | 0.72 |
5yr Avg Net Profit Margin
|
23.09 % | 13.0 % | 24.8 % |
Price to Book
|
2.21 | 3.54 | 5.58 |
P/E
|
8.48 | 28.58 | 27.55 |
5yr Avg Cash Conversion Cycle
|
10.54 Days | 1.45 Days | 79.85 Days |
Inventory Days
|
99.95 Days | 94.67 Days | 64.55 Days |
Days Receivable
|
86.16 Days | 60.69 Days | 100.92 Days |
Days Payable
|
154.15 Days | 176.63 Days | 74.04 Days |
5yr Average Interest Coverage Ratio
|
46.61 | 36.16 | 579.71 |
5yr Avg ROCE
|
16.05 % | 17.34 % | 25.27 % |
5yr Avg Operating Profit Margin
|
30.17 % | 19.56 % | 30.87 % |
5 yr average Debt to Equity
|
0.06 | 0.2 | 0.01 |
5yr CAGR Net Profit
|
24.68 % | -5.77 % | 16.28 % |
5yr Average Return on Assets
|
11.07 % | 10.48 % | 17.7 % |
Shareholdings
|
|||
Promoter Holding
|
49.56 % | 69.67 % | 70.56 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.75 % | 0.06 % | 1.67 % |
Change in Mutual Fund Holding (3 Yrs)
|
-5.54 % | 4.02 % | 0.55 % |
Natco Pharma
|
Alembic Pharma
|
Caplin Point Lab
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
-
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|